Business Wire

Five New Consumer Wearable Products Powered by Movesense to be Showcased at CES 2019

Jaa

Five companies launching new wearable devices that provide more targeted, accurate, and consistent data for consumers tracking health, athletic performance, stress, and more will exhibit in one place at the International Consumer Electronics Show (CES) 2019, held from January 8-11, 2019. The products rely on Movesense’s motion sensing technology and sensor platform to improve athletic training, avoid costly medical interventions in elderly patients, and manage stress for people in demanding occupations. These new devices will be on display at the Movesense-Suunto booth, #44537.

“We were one of nine companies selected to take part in 1st and Future, a sports tech pitch contest sponsored by the NFL,” said David Troup, founder of Konect Sports. “We went from that pitch to a product in 10 months. While developing our first product, Konect Speed Training, we conceived of a second product, the Konect Speed Pro, which we developed in seven weeks. We could not have done this without Movesense.”

Suunto started developing Movesense for its own line of smartwatches in 2015, but soon realized that it could accelerate the growth of the wearables market by making a programmable sensor available. Because its open development environment is easy to use, early adopters of Movesense have been able to focus on smaller sports in which there are few products and other so-called edge cases.

“With Movesense, we get the benefit of tried and tested hardware that features open source software and is cost-effective,” said Konrad Antoniuk, founder of Morph Wear. “That has reduced the number of technical challenges we face in developing a product, and has allowed us to focus on designing our applications and making the user experience better.”

The companies that will display their products alongside Movesense in booth #44537 in the Sands Expo Convention Center at CES include:

  • Konect Sports, a U.S.-based reaction, speed and agility training system that allows coaches and athletes to track and analyze data at an extremely granular level. The company has commercialized two products that rely on the Movesense platform in just under a year: Konect Speed Pro and the new Konect Speed Training. Both products are multi-sensor applications that harness data to improve reaction time, agility, and speed in athletes at all levels.
  • Morph Wear, a swimming analytics solution driven by a two-person team that discovered Movesense at CES 2018. Morph Wear improves swimming workouts and training efficiency by letting swimmers know when they are under or over performing based on metrics that measure intensity. Early versions of the Morph Wear device have been used by Olympic athletes to inform the Morph Wear system and identify several data-driven elite performance characteristics.
  • W2ND, pronounced Second Wind, uses Movesense’s built-in non-medical ECG capabilities to calculate a real-time lactate threshold measurement. The sensor relies on research that shows how heart rate variability correlates to lactate thresholds. W2ND’s intuitive analytics platform can be used by elite athletes, weekend warriors, and anyone seeking to lose weight to improve endurance and overall fitness. The company advanced its timeline for release, discovering Movesense this year after trying to develop its own sensor technology.
  • ALMA.care, a Belgian digital health tech company, uses foot-worn Movesense sensors and a wrist band to study subtle changes in people's data and detect signs of health and mobility issues in the elderly. Because small issues can be signs of underlying problems that may require expensive interventions if left untreated, ALMA.care health & gait analysis technology can justify early treatment that is far less costly and invasive.
  • Overskudd, a Norwegian technology firm developing solutions to enhance human performance. Products include the Overskudd sensor (Movesense with Overskudd HRV library and firmware), Chester and Chester Jr. (Connectors for using Movesense with Electrodes) and the Overskudd Analysis Server (a cloud platform for performance analysis, enhancement and prediction). Clients include individuals, corporations, athletes, Special Forces, athletes and research institutions worldwide.

Together, the companies will demonstrate how Movesense’s ready-to-use sensors and open development platform, released just 18 months ago, can be used to quickly develop wearable technology products that address novel challenges and applications.

“This past year has shown that developers can achieve amazing things when we give them the tools they need,” said Terho Lahtinen, Senior Manager, Future Concepts at Movesense. “With Movesense, entrepreneurs get the tools they need to solve the problems they are passionate about - be it in sports, medicine, wellness, occupational safety, and more – at a fraction of the cost and time.”

For more information on Movesense, please visit movesense.com .

About Movesense

Movesense is an open development environment for motion-sensing solutions. Developed in Finland by Suunto, its easy and innovative tools accelerate measuring and sensing applications across sports, agriculture, manufacturing, health care, and more. Learn more at www.movesense.com/.

Developers interested in incorporating Movesense motion-sensing technology into their prototypes or current products can order a software development kit here.

About Suunto

Suunto is a Finnish manufacturer of world renowned sports watches, dive computers and precision instruments for the toughest conditions. Find out more about the company and its products at www.suunto.com.

Contact information

Gregory FCA for Movesense
Matt McLoughlin
610-228-2123
Matt@GregoryFCA.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 15:00:00 EETTiedote

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 14:30:00 EETTiedote

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 13:45:00 EETTiedote

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 13:00:00 EETTiedote

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 13:00:00 EETTiedote

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr

SmartStream Partners with Cassini Systems to Help Firms Meet Uncleared Initial Margin Obligations20.3.2019 12:00:00 EETTiedote

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced its partnership with Cassini Systems, the leading provider of pre and post trade margin analytics for buy side derivatives trading, to help financial institutions comply with BCBS-IOSCO margin requirements for uncleared OTC derivatives. BCBS-IOSCO defines rules for margin requirements on Uncleared Over-the-Counter (OTC) derivatives known as Uncleared Margin Rules (UMR). ISDA has developed a Standard Initial Margin Model (SIMM) that can be used by market participants to provide a transparent and standardised margin methodology of bi-lateral trades. The roll out of UMR rules has now reached the buy side with phase 4 firms coming into scope in September 2019, and phase 5 firms in September 2020. SmartStream’s TLM Collateral Management provides firms with automated data management to reduce operational risks associated with collateral management. This partnership will integra

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme